Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602207 · ClinicalTrials.gov registry record · Phase 4
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
A Phase 4 study, sponsored by Innovaderm Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT05602207 is a Phase 4 study that has completed, run by Innovaderm Research. The registered enrollment target is 24 participants.
The verdict
NCT05602207, a Phase 4 study, has completed, sponsored by Innovaderm Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
Interventions
- DRUG Abrocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-11-25 |
| Est. Completion | 2025-01-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05602207
The ClinicalTrials.gov registry entry for NCT05602207 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innovaderm Research, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abrocitinib is the first listed.
NCT05602207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05602207 about?
NCT05602207 is a clinical study titled "Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab". This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
What is the current status of trial NCT05602207?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2022-11-25. Estimated completion is 2025-01-09.
What interventions are being tested in trial NCT05602207?
The interventions under investigation include: Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT05602207?
This trial is sponsored by Innovaderm Research, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.